Company intelligence / Profile preview

Kinea Bio

Seattle, Washington, USAkineabio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Developing next-generation gene therapies for neuromuscular diseases, with a breakthrough gene therapy strategy for DMD published in Nature in July 2024

Therapeutic areas: Rare DiseasesNeurology
Modalities: AAV-based gene therapies
Industry: Biotech

Drug pipeline

8 assets

KNA-145

Preclinical

7 more assets in the full pipeline.

Request access →

Partnerships

Parent Project Muscular DystrophyThe Speak FoundationCureLGMD2iUniversity of Washington's Center for Translational Muscle ResearchNIH (SBIR funding)

Beyond the preview

Go deeper on Kinea Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kinea Bio.

Explore the full profile